Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa ...

The launch marked Danish drugmaker Novo Nordisk's debut on the continent, ramping up competition with rival Eli Lilly.

By Nqobile Dludla and Siyanda Mthethwa JOHANNESBURG (Reuters) -Danish drugmaker Novo Nordisk introduced its weight-loss drug ...

Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa, marking its debut in Africa and ...

Sales of weight loss drug Wegovy more than doubled in the final three months of 2024 but its manufacturer has predicted growth will slow this year. Novo Nordisk's rise to become one of Europe's ...

Since July 2024, Wegovy has been approved to help lower the risk of heart attacks and strokes in people with circulatory and heart diseases, those with a BMI of more than or equal to 27, and those ...

At his home in Denmark Casper Nielsen retrieves a package from the fridge and prepares to inject his next dose. "So this is Wegovy, you take it four times a month," says the 45-year-old. "Before ...

Wegovy belongs to a group of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists. It contains the active ingredient semaglutide, which mimics the activity of our brain’s natural GLP-1.

COPENHAGEN--Novo Nordisk will launch its hugely popular anti-obesity drug Wegovy in Japan on Feb. 22 next year, its first launch in Asia, the company said on Thursday, even as it struggles to keep ...

Danish pharma giant Novo Nordisk A/S is set to launch its blockbuster glucagon-like peptide-1 therapy, Wegovy (semaglutide), in South Korea’s growing obesity therapeutics market next week, a company ...